These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10096581)

  • 21. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine.
    Hel Z; Johnson JM; Tryniszewska E; Tsai WP; Harrod R; Fullen J; Tartaglia J; Franchini G
    Vaccine; 2002 Aug; 20(25-26):3171-86. PubMed ID: 12163269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
    Watkins JD; Lancelot S; Campbell GR; Esquieu D; de Mareuil J; Opi S; Annappa S; Salles JP; Loret EP
    Retrovirology; 2006 Jan; 3():8. PubMed ID: 16441880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL.
    Dominici S; Laguardia ME; Serafini G; Chiarantini L; Fortini C; Tripiciano A; Brocca-Cofano E; Scoglio A; Caputo A; Fiorelli V; Gavioli R; Cafaro A; Ensoli B; Magnani M
    Vaccine; 2003 May; 21(17-18):2073-81. PubMed ID: 12706697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
    Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
    Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.
    Cohen SS; Li C; Ding L; Cao Y; Pardee AB; Shevach EM; Cohen DI
    Proc Natl Acad Sci U S A; 1999 Sep; 96(19):10842-7. PubMed ID: 10485913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
    Partidos CD; Moreau E; Chaloin O; Tunis M; Briand JP; Desgranges C; Muller S
    Eur J Immunol; 2004 Dec; 34(12):3723-31. PubMed ID: 15549730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
    Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
    J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
    Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B
    Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 Tat vaccines.
    Ensoli B; Cafaro A
    Virus Res; 2002 Jan; 82(1-2):91-101. PubMed ID: 11885958
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
    Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
    DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
    Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
    Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 Tat-based vaccines: from basic science to clinical trials.
    Fanales-Belasio E; Cafaro A; Cara A; Negri DR; Fiorelli V; Butto S; Moretti S; Maggiorella MT; Baroncelli S; Michelini Z; Tripiciano A; Sernicola L; Scoglio A; Borsetti A; Ridolfi B; Bona R; Ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Vardas E; Magnani M; Laguardia E; Caputo A; Titti F; Ensoli B
    DNA Cell Biol; 2002 Sep; 21(9):599-610. PubMed ID: 12396602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Ebensen T; Link C; Becker PD; Fiorelli V; Cafaro A; Ensoli B; Guzmán CA
    Vaccine; 2006 Mar; 24(12):2049-56. PubMed ID: 16406225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
    Gringeri A; Musicco M; Hermans P; Bentwich Z; Cusini M; Bergamasco A; Santagostino E; Burny A; Bizzini B; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):358-70. PubMed ID: 10096580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant.
    Patel J; Galey D; Jones J; Ray P; Woodward JG; Nath A; Mumper RJ
    Vaccine; 2006 Apr; 24(17):3564-73. PubMed ID: 16516358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.